Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating and preventing obesity and non-alcoholic fatty liver disease

A non-alcoholic, fatty liver technology, applied in the hawthorn flavonoid-total tanshinone composition, the application field in the preparation of drugs and/or health care products for preventing and/or treating non-alcoholic fatty liver, can solve the problem of uneconomical, easy-to-obtain, The efficacy of synergistic gain needs to be studied, and the treatment effect of a single component is not discussed, so as to achieve the effect of streamlining raw materials, relieving excessive weight gain, and reducing fat accumulation in liver tissue

Inactive Publication Date: 2019-08-16
阎永平
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2) Raw materials are mostly used, and then boiled and decocted; no extraction and refining steps are included, and potential liver and kidney toxicity cannot be avoided
4) Only the overall efficacy of the composition is verified, and the therapeutic effect of a single component is not discussed; the synergistic effect of each component needs to be studied
5) Some selected drugs are not economically available, such as Cordyceps sinensis, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating and preventing obesity and non-alcoholic fatty liver disease
  • Pharmaceutical composition for treating and preventing obesity and non-alcoholic fatty liver disease
  • Pharmaceutical composition for treating and preventing obesity and non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1 Hawthorn flavonoids-total tanshinone for the prevention and treatment of non-alcoholic fatty liver and obesity caused by high-fat diet model

[0063] 1. Instruments and materials

[0064] Main instruments: electronic balance (Shanghai METTLER TOLEDO); full-wavelength microplate reader (Thermo Company, USA); centrifuge (Eppendorf Company, Germany); low-speed desktop centrifuge (HKUST Zhongjia).

[0065] Drugs and reagents: 60% high-fat feed (TP2330055A) and its control feed (TP 2330055AC, Nantong Trophy Feed Technology Co., Ltd.); 80% hawthorn flavonoids, 40% total tanshinone (Shaanxi Senlang Biochemical Co., Ltd.); ALT , AST, TC, TG detection kits (Nanjing Jiancheng Institute of Bioengineering); other reagents were of analytical grade.

[0066] 2. Preparation of hawthorn flavonoids-total tanshinone composition

[0067] According to the dosage, the hawthorn flavonoids are 50, 100 mg / kg; the total tanshinone is 50, 100 mg / kg. The estimated dosage of the purch...

Embodiment 2

[0093] Example 2: Preparation of tablets and capsules comprising 11-99% hawthorn flavonoids-total tanshinone:

[0094] Take hawthorn flavonoids-total tanshinone dry powder, pass through a 60-100 mesh sieve for later use. (1) Add one or several kinds of excipients commonly used in tablets; compress into tablets by a tablet machine. Each tablet contains no less than 110 mg of components, and the weight of the tablet can be adjusted according to the drug loading.

[0095](2) Add one or several kinds of auxiliary materials commonly used in capsules, granulate, granulate, and pack into capsules. Each capsule contains no less than 110 mg of components, and the weight of the capsule can be adjusted according to the drug loading. See Table 5. Suggested dosage: 6 capsules per day, 2 capsules per meal, 110-220mg extract per capsule; daily intake is 660-1320mg. Or take 3 capsules per day, 1 capsule per meal, 220-440mg extract per capsule; the daily intake is 660-1320mg. Or take 2 ca...

Embodiment 3

[0105] Example 3: Preparation of granules and suspensions containing 3-99% hawthorn flavonoids-total tanshinone: taking 10g / bag as an example, the specific dosage form specification (weight / bag) can be adjusted according to the drug loading. Take hawthorn flavonoids-total tanshinone dry powder, pass through a 60-100 mesh sieve for later use. Take 330-1320g of the above-mentioned dry powder, arbitrarily proportioning 8680-9670g of auxiliary materials; make the total weight 10000g. Add a small amount of solvent and mix well to make granules, dry, pack one bag per 10g; 1000 bags in total. The excipients include, but are not limited to: sweeteners, powdered sugar, dextrin, β-cyclodextrin, and effervescent disintegrants. The prepared hawthorn flavonoid-total tanshinone granule contains 3.3-13.2% of active ingredients in each bag. Suggested dosage: take 1-2 bags per day, with a daily intake of 660-1320mg. See Table 6. On the premise of considering different dosage forms, it is e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine. The invention relates to a hawthorn flavone-total tanshinone composition and an application thereof in preparation of drugs and / or health care productsfor preventing and / or treating non-alcoholic fatty liver. The invention also provides an application of the hawthorn flavone-total tanshinone composition in health care products, and drinks prepared by taking the hawthorn flavone-total tanshinone composition as an active ingredient and mixing with food acceptable additives; the invention provides but is not limited to alcoholic blended drinks, fruit beer drinks, added type grape wine, flavored grape wine drinks and the like. The hawthorn flavone-total tanshinone composition is found out to be able to prevent and treat non-alcoholic fatty liver, obesity and hyperlipidemia caused by long-term feeding with high-fat feeds. The oxidation resistance of hawthorn and the lipid-lowering effect of salvia miltiorrhiza are fully combined, all pathological indicators are improved comprehensively, and the non-alcoholic liver disease and obesity are alleviated. The composition is relatively simple, the dosage is relatively low, and the adverse reactions and the burden of liver and kidney are obviously reduced.

Description

technical field [0001] The invention belongs to the field of medicine. Composition and application related to hawthorn flavonoids and total tanshinone. More specifically, it relates to hawthorn flavonoids-total tanshinone composition and its application in the preparation of drugs and / or health products for the prevention and / or treatment of non-alcoholic fatty liver; / or application in medicines and / or health care products for the treatment of obesity. The above-mentioned extracts can be obtained by different processes. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) refers to a syndrome characterized by excessive fat deposition in liver cells caused by alcohol and other definite liver damage factors; including simple fatty liver, fatty liver hepatitis and its associated cirrhosis. With the improvement of per capita living standards, NAFLD has become an important cause of chronic liver disease in Europe, America and my country. The prevalence of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/734A61P3/04A61P1/16C12G3/055C12G1/00C12C5/02
CPCA23V2002/00A61K36/537A61K36/734A23L33/105C12C5/02C12G1/00C12G3/04A61K2300/00A23V2200/32A23V2200/332A23V2250/2116A23V2250/5118A23V2250/51084A23V2250/51082A23V2250/51088A23V2250/5112A23V2250/5114A23V2250/612
Inventor 胡冰芳
Owner 阎永平
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com